Pharmaceutical Technology

FEBRUARY 13, 2023

Elyxyb is a prescription nonsteroidal anti-inflammatory drug (NSAID) used for acute migraine treatment in adult patients with or without aura. It is formulated using a self-micro-emulsifying drug delivery system that improves the drug’s bioavailability and solubility.

Drug Delivery Systems 130

Drug Delivery Systems FDA Approval Bioavailability Drug Delivery 130

Outsourcing Pharma

AUGUST 8, 2022

The pharmaceutical company has forged a partnership with the nanotechnology specialist to use nanoparticle tech and formulation to advance its products.

Bioavailability 52

Bioavailability Branding Medicine Production 52

XTalks

AUGUST 30, 2022

One of the biggest challenges with developing therapies to treat CNS disorders is the delivery of systemically administered investigational products (IPs) to the brain, which is limited by the blood-brain barrier. Some methods of direct CNS administration include intrathecal, intraparenchymal and intracerebroventricular (ICV) delivery.

Trials 83

Trials Drug Delivery Drugs Gene 83

Roots Analysis

SEPTEMBER 1, 2023

By using real-world evidence , researchers can gain clinically useful insights that can help improve the quality of care delivery in precision medicine. As the field continues to advance, it is expected to have a profound impact on the future of medicine.

Drug Delivery 52

Drug Delivery Marketing Drug Delivery Systems Drugs 52

The Pharma Data

JANUARY 27, 2021

Further to XPhyto’s press release dated January 18, 2021, the Company’s core milestones for this year include the commercialization of infectious disease diagnostics, the clinical validation of transdermal and sublingual drug formulations and continued investment in psychedelic medicine. About XPhyto Therapeutics Corp.

Drugs 52

Drugs Manufacturing Drug Delivery Production 52

The Pharma Data

NOVEMBER 26, 2020

As drug molecules become more complex so do the options to deliver them. This novel nanoparticle formation technology provides hope for improving the possibilities and probabilities of developing better medicines for patients and it expands Nanoform’s reach into the growing biological market. HELSINKI , Nov. Finnish time.

Containment 52

Containment Medicine Development Bioavailability 52

The Pharma Data

JANUARY 3, 2021

4, 2021 /PRNewswire/ — Nanoform Finland Plc (“Nanoform”), an innovative nanoparticle medicine enabling company, today announced a new near-term business target. Nanoform is an innovative nanoparticle medicine enabling company. HELSINKI , Jan. Finnish time. About Nanoform.

Containment 40

Containment Bioavailability Clinical Trials Clinical Trials 40